Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.

Investigation Reveals Deep Flaws in FDA Drug Approval Process, Raising Concerns Over Public Safety** A recent investigative report has uncovered alarming findings regarding the ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly ...

A groundbreaking study from the Centre for Addiction and Mental Health (CAMH) in Canada has revealed that an experimental ...

The three philanthropists devoted themselves and their resources to important causes during lifetimes of service to Palm Beach and beyond.

Saturday at the Dream Center, the Bismarck Memory Cafe hosted a presentation from the Alzheimer’s Association about recent ...

Alzheimer's disease progression linked to microglia fat metabolism, potential new treatment target identified in recent study ...

AAPLOG Vice Chair Dr. Susan Bane discusses the potential health risks of abortion drugs like mifepristone on ‘Fox & Friends ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...